CASP8 and infection: These data indicate that deletion of RIPK3 does not preclude imatinib from limiting the pathology associated with granulomatous lesions; moreover, the capacity of imatinib to limit pathology of granulomatous lesions resulting from Mm infection was abrogated in mice lacking CASP8.